←Back to Expert Scholars
Translational Medicine / 转化医学KRAS Inhibitors, Thoracic Oncology
Daniel Morgensztern
MD
🏢Washington University in St. Louis🌐USA
Professor of Medicine, Oncology
50
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Daniel Morgensztern is a thoracic oncologist leading KRAS inhibitor and combination trials at Washington University. He co-authors consensus reviews on NSCLC subtypes and targeted therapy sequencing. His work addresses acquired resistance to G12C agents.
Share:
🧪Research Fields 研究领域
NSCLC
KRAS G12C
small cell lung cancer
clinical trials
targeted therapy
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Daniel Morgensztern 的研究动态
Follow Daniel Morgensztern's research updates
留下邮箱，当我们发布与 Daniel Morgensztern（Washington University in St. Louis）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment